Evaluation of a new screening assay, protein C pathway (PCP) test, for identification of defects in the protein C pathway.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to C Neuwald.
Explore the source record for details and available documents.
Serum samples of 151 intravenous drug users were tested for markers of hepatitis B, hepatitis C, HIV and HTLV-I infection to estimate the prevalence of blood born virus infection in this high risk group. Anti HCV antibodies were found in 75% of sera. Seroprevalence for HIV was found 13%, for hepatitis B markers 68% and none for HTLV-I. Multiple infections have been very frequent.
In patients with malaria the lipid parameters triglycerides, cholesterol, and HDL-cholesterol were determined routinely. At the time of admission hypertriglyceridemia, hypocholesterolemia, and an extreme decrease in HDL-cholesterol were found. This dyslipoproteinemia was present in cases of falciparum malaria, as well as in cases of benign tertian malaria. The extent of HDL-cholesterol decrease showed no correlation to the severity of the clinical course of disease. HDL-cholesterol has proven to be an independent diagnostic laboratory finding in cases of suspected malarial infection. This parameter displays high diagnostic sensitivity, but no specificity for malaria.
We evaluated a new dry-reagent carrier system for the determination of creatine kinase (EC 2.7.3.2) activity, Reflotron CK, with special attention to analytical performance with whole blood. We found a good within series imprecision. The median coefficient of variation was 3.1% for Reflotron CK (blood, serum and plasma) and 0.9% for the automatic analysers (serum and plasma only). The between-days imprecision with Reflotron CK (median CV: less than or equal to 3%) was similar to that for the comparison method on different analysers. Fresh samples of human blood, plasma and serum were examined by Reflotron CK and by a N-acetylcysteine activated creatine kinase method in six different clinical laboratories and in the Evaluation Department of Boehringer Mannheim GmbH. The correlation between these methods was excellent (r greater than or equal to 0.99), the median systematic deviation (bias) for all samples being smaller than -5%. Haematocrits between 0.25 and 0.50, haemolysis up to 6 g/l haemoglobin, and icteric samples with bilirubin concentrations up to 0.2 g/l showed no interference. No drug in therapeutic concentration was found to affect the Reflotron CK results; ascorbic acid, calcium dobesilate and sulphamethoxazole lowered the values only when present in high concentrations. Reflotron CK may be considered as a suitable alternative for decentralized testing sites, especially in situations where creatine kinase results are needed quickly.
Sera of 71 intravenous drug abusers imprisoned in Austria were tested for HTLV-III antibodies and the results correlated with the case histories and available clinical data. 12 sera, i.e. 17%, were found to be positive. Seronegative and seropositive drug addicts showed no notable difference regarding the average duration of previous drug abuse or the incidence of sexually-transmitted diseases. Among HTLV-III seropositive drug addicts there was found to be a significantly higher incidence of frequent needle-sharing and history of previous i.v. drug abuse in Amsterdam. 6 of 12 HTLV-III seropositive drug addicts had developed the lymphadenopathy syndrome (LAS); chronic liver disease and positive hepatitis B serology were equally frequent in HTLV-III seronegative persons, HTLV-III seropositive persons without symptoms and LAS patients.
A case report is presented of the rare haemoglobinopathy HbS-thalassaemia, type betaS-betathal-O in a Greek family. The special diagnostic features are discussed, with particular reference to the differential diagnosis.
UNLABELLED: From 1985 to 1990 the sera of 372 newly imprisoned intravenous drug users (IDU) were tested for HIV-1 antibodies. The seroprevalence was 18%, males 16% and females 31%. HIV-1 seroprevalence in Austrian IDU has not increased since 1986. All sera tested for HTLV-I-antibodies were negative. The majority of the HIV-1 seropositive drug users had been infected before 1985. The reported frequency of needle sharing has decreased since 1986. Of 151 IDU tested for HCV antibodies 75% were positive for anti-HCV, 68% were positive for hepatitis B markers, 59% were positive for both HBV and HCV markers, and 13% were positive for HIV-1 antibodies. IN CONCLUSION: in Austrian IDU HCV seems to be the most frequent parenterally transmitted virus; HIV-1 seroprevalence has not increased since 1986; HLTV-I infection has not yet begun.